Infrared Spectroscopy in Differential Diagnosis of Pulmonary Embolism

The aim of the study was to assess the effectiveness of infrared spectroscopy for verification of pulmonary embolism (PE) and a number of similar diseases.

Materials and Methods. Infrared spectroscopy was used to investigate blood serum of 19 healthy volunteers and 30 patients with intraoperatively confirmed PE as well as with chronic obstructive pulmonary disease (COPD) (n=10), pneumonia (n=10), tuberculosis (n=10), lung abscess (n=10) and lung cancer (n=10), acute disorder of cerebral circulation (ADCC) (n=10), ischemic heart disease (IHD) (n=10). Peak height ratios of absorption band were taken as diagnostic parameters (cm^–1/сm^–1): P₁ — 1160/1165; P₂ — 1165/1070; P₃ — 1165/1150; P₄ — 1165/1050; P₅ — 1100/1050; P₆ — 1025/1165. These parameters of IR spectrum are significant for the given nosology.

Results. The calculated indicators have demonstrated statistically significant difference of IR spectra parameters for the studied nosologies (p<0.001) even on the small samples supplementing each other and enabling step-by-step exclusion of lung abscess and pulmonary tuberculosis, COPD and pneumonia, cancer, IHD, ADCC, and PE.

The presented radar charts, built with consideration of the values of all peak height ratios of the absorption bands with diagnostically significant maxima, provided the possibility to visualize the IR profiles making the differentiation of PE and its clinical analogs not only more objective and reliable but also more explicit and compelling.

Conclusion. Infrared spectroscopy is a potentially effective method of PE differential diagnosis. Sample expansion will allow researchers to evaluate the sensitivity and specificity of this technique compared to the existing standard schemes of PE verification.

1. Bagrova I.V., Kukharchik G.A., Serebriakova V.I., Konstantinova I.V., Kaputin M.Iu. The modern approaches to diagnostics of pulmonary embolism. Flebologiya 2012; 6(4): 35–42.
2. Chuchalin A.G. Pul’monologiya [Pulmonology]. Moscow: GEOTAR-Media; 2014; 800 p. URL: http://www.rosmedlib.ru/book/ISBN9785970427712.html.
3. Cherkasova N.A., Sergeeva E.V. Differentsial’naya diagnostika pri bolyakh v grudnoy kletke [Differential diagnosis for chest pain]. Moscow: GEOTAR-Media; 2009.
4. Jolobe O.M.P. Pulmonary embolism in the differential diagnosis of right ventricular myocardial infarction. Am J Emerg Med 2019; 37(8): 1591–1592, https://doi.org/10.1016/j.ajem.2019.05.059.
5. Fedchenko Ya.O., Protopopov A.V., Kochkina T.A., Stoliarov D.P., Konstantinov E.P., Gavrikov P.G. Efficacy of the treatment of pulmonary embolism depending on the time of patients’ admission. Mezhdunarodnyj zhurnal intervencionnoj kardioangiologii 2010; 21: 33–36.
6. Fang M.C., Fan D., Sung S.H., Witt D.M., Schmelzer J.R., Williams M.S., Yale S.H., Baumgartner C., Go A.S. Treatment and outcomes of acute pulmonary embolism and deep venous thrombosis: the CVRN VTE Study. Am J Med 2019; 132(12): 1450–1457.E1, https://doi.org/10.1016/j.amjmed.2019.05.040.
7. O’Connell C., Montani D., Savale L., Sitbon O., Parent F., Seferian A., Bulifon S., Fadel E., Mercier O., Mussot S., Fabre D., Dartevelle P., Humbert M., Simonneau G., Jaïs X. Chronic thromboembolic pulmonary hypertension. La Presse Médicale 2015; 44(12 Pt 2): e409–e416, https://doi.org/10.1016/j.lpm.2015.10.010.
8. Tudela P., Mòdol J.M., Rego M.J., Bonet M., Vilaseca B., Tor J. Error diagnóstico en urgencias: relación con el motivo de consulta, mecanismos y trascendencia clínica. Med Clin (Barc) 2005; 125(10): 366–370, https://doi.org/10.1157/13079168.
9. Lang I.M., Pesavento R., Bonderman D., Yuan J.X.-J. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41(2): 462–468, https://doi.org/10.1183/09031936.00049312.
10. Pepke-Zaba J., Delcroix M., Lang I., Mayer E., Jansa P., Ambroz D., Treacy C., D’Armini A.M., Morsolini M., Snijder R., Bresser P., Torbicki A., Kristensen B., Lewczuk J., Simkova I., Barberà J.A., de Perrot M., Hoeper M.M., Gaine S., Speich R., Gomez-Sanchez M.A., Kovacs G., Hamid A.M., Jaïs X., Simonneau G. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124(18): 1973–1981, https://doi.org/10.1161/circulationaha.110.015008.
11. Pepke-Zaba J., Jansa P., Kim N.H., Naeije R., Simonneau G. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013; 41(4): 985–990, https://doi.org/10.1183/09031936.00201612.
12. Yandrapalli S., Tariq S., Kumar J., Aronow W.S., Malekan R., Frishman W.H., Lanier G.M. Chronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, and management. Cardiol Rev 2018; 26(2): 62–72, https://doi.org/10.1097/crd.0000000000000164.
13. Nižňanský M., Ambrož D., Prskavec T., Jansa P., Lindner J. Surgical treatment of chronic thromboembolic pulmonary hypertension. Vnitr Lek 2019; 65(5): 353–358.
14. Jenkins D., Madani M., Fadel E., D’Armini A.M., Mayer E. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26(143): 160111, https://doi.org/10.1183/16000617.0111-2016.
15. Chazova I.E., Martynyuk T.V., Valieva Z.S., Nakonechnikov S.N., Nedogoda S.V., Salasyuk A.S., Taran I.N., Gratsianskaya S.E. The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation. Terapevticheskij arhiv 2018; 90(9): 101–109.
16. Grosse S.D., Nelson R.E., Nyarko K.A., Richardson L.C., Raskob G.E. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016; 137: 3–10, https://doi.org/10.1016/j.thromres.2015.11.033.
17. Kirson N.Y., Birnbaum H.G., Ivanova J.I., Waldman T., Joish V., Williamson T. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. Appl Health Econ Health Policy 2011; 9(6): 377–387, https://doi.org/10.2165/11592440-000000000-00000.
18. Grobben R.B., Frima C., Nathoe H.M., Leiner T., Kwakkel-van Erp J.M., van Klei W.A., Peelen L.M., van Herwaarden J.A. Pulmonary embolism after endovascular aortic repair, a retrospective cohort study. Eur J Vasc Endovasc Surg 2019; 57(2): 304–310, https://doi.org/10.1016/j.ejvs.2018.08.054.
19. Hyde Congo K., Tomás A., Laranjeira Á., Afonso D., Fragata J. Type B aortic dissection with retrograde intramural hematoma and pulmonary embolism. Rev Port Cir Cardiotorac Vasc 2018; 25(1–2): 73–76.
20. Ruiz-Artacho P., Trujillo-Santos J., López-Jiménez L., Font C., Díaz-Pedroche M.D.C., Sánchez Muñoz-Torrero J.F., Peris M.L., Skride A., Maestre A., Monreal M.; RIETE Investigators. Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism. TH Open 2018; 2(2): e210–e217, https://doi.org/10.1055/s-0038-1656542.
21. Ateş H., Ateş İ., Bozkurt B., Çelik H.T., Özol D., Yldrm Z. What is the most reliable marker in the differential diagnosis of pulmonary embolism and community-acquired pneumonia? Blood Coagul Fibrinolysis 2016; 27(3): 252–258, https://doi.org/10.1097/mbc.0000000000000391.
22. Gordetsov A.S., Krasnikova O.V., Nemirova S.V., Medvedev A.P. Diagnostic technique for pulmonary thromboembolism. Patent RU 2527346. 2014.
23. Zhang Y., Zhou Q., Zou Y., Song X., Xie S., Tan M., Zhang G., Wang C. Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study. J Thromb Thrombolysis 2016; 41(4): 619–627, https://doi.org/10.1007/s11239-015-1275-6.
24. Olson J.D., Adcock D.M., Bush T.A., de Moerloose P., Gardiner C., Ginyard V.R., Grimaux M., McMahan C.A., Prihoda T.J., Rico-Lazarowski A., Sales M., Stang L., Trumbull K., Van Cott E., Wissel T. Quantitative D-dimer for exclusion of venous thromboembolic disease; approved guideline. H-59A. Clinical and Laboratory Standards Institute; 2011.
25. Zhang C., Jiang L., Xu L., Tian J., Liu J., Zhao X., Feng X., Wang D., Zhang Y., Sun K., Xu B., Zhao W., Hui R., Gao R., Yuan J., Song L. Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease. Eur Heart J 2019; 40(41): 3397–3405, https://doi.org/10.1093/eurheartj/ehz394.
26. Lin S.C., Tsai Y.J., Huang C.T., Kuo Y.W., Ruan S.Y., Chuang Y.C., Yu C.J. Prognostic value of plasma N-terminal pro B-type natriuretic peptide levels in pneumonia patients requiring intensive care unit admission. Respirology 2013; 18(6): 933–941, https://doi.org/10.1111/resp.12096.
27. Mueller C., McDonald K., de Boer R.A., Maisel A., Cleland J.G.F., Kozhuharov N., Coats A.J.S., Metra M., Mebazaa A., Ruschitzka F., Lainscak M., Filippatos G., Seferovic P.M., Meijers W.C., Bayes-Genis A., Mueller T., Richards M., Januzzi J.L.J.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21(6): 715–731, https://doi.org/10.1002/ejhf.1494.

Krasnikova O.V., Nemirova S.V., Medvedev A.P., Gordetsov A.S. Infrared Spectroscopy in Differential Diagnosis of Pulmonary Embolism. Sovremennye tehnologii v medicine 2020; 12(3): 64, https://doi.org/10.17691/stm2020.12.3.08